Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chianese

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Journal for Immunotherapy of Cancer|May 26, 2021
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonistMax O Meneveau, Gina R Petroni, Elise P Salerno, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancerKimberly A Chianese-Bullock, William P Irvin, Gina R Petroni, et al.
Molecular Oncology|March 30, 2013
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancerJeffrey B Smerage, G Thomas Budd, Gerald V Doyle, et al.
Journal for Immunotherapy of Cancer|June 29, 2019
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patientsMarit M Melssen, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant settingCraig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancerPatrick M Dillon, Gina R Petroni, Mark E Smolkin, et al.
Annals of Surgical Oncology|October 17, 2008
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesCraig L Slingluff, Galina V Yamshchikov, Kevin T Hogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigensCraig L Slingluff, Gina R Petroni, Walter Olson, et al.
Cancer Research Communications|April 10, 2026
Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab)Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|May 26, 2021
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonistMax O Meneveau, Gina R Petroni, Elise P Salerno, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancerKimberly A Chianese-Bullock, William P Irvin, Gina R Petroni, et al.
Molecular Oncology|March 30, 2013
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancerJeffrey B Smerage, G Thomas Budd, Gerald V Doyle, et al.
Journal for Immunotherapy of Cancer|June 29, 2019
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patientsMarit M Melssen, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant settingCraig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancerPatrick M Dillon, Gina R Petroni, Mark E Smolkin, et al.
Annals of Surgical Oncology|October 17, 2008
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesCraig L Slingluff, Galina V Yamshchikov, Kevin T Hogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigensCraig L Slingluff, Gina R Petroni, Walter Olson, et al.
Cancer Research Communications|April 10, 2026
Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab)Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, et al.
Pageof 6